2-(6-chloro-pyridin-2-yloxy)-2-methyl-propionic acid | 605681-23-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(6-chloro-pyridin-2-yloxy)-2-methyl-propionic acid
• 英文别名: 2-(6-chloropyridin-2-yl)oxy-2-methylpropanoic acid
• CAS: 605681-23-0
• 化学式: C₉H₁₀ClNO₃
• 分子量: 215.636
• InChiKey: YJFNJULAERNUBY-UHFFFAOYSA-N

物化性质

• 沸点：
  329.0±27.0 °C(Predicted)
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(6-chloro-pyridin-2-yloxy)-2-methyl-propionic acid 在 吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.08h， 生成 2-(6-chloro-pyridin-2-yloxy)-N-(3-methanesulfonylamino-pyridin-2-yl)-2-methyl-propionamide
  参考文献：
  名称：

  WO2008/104994

  摘要：

  公开号：

文献信息

• Substituted amides
  申请人：Lin Linus S.

  公开号：US20080194645A1

  公开（公告）日：2008-08-14

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，并且可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作中枢神经系统药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病，包括多发性硬化症和格林-巴利综合症以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍以及哮喘、便秘、慢性肠假性梗阻和肝硬化。
• 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION
  申请人：Mookhtiar Kasim A.

  公开号：US20100144772A1

  公开（公告）日：2010-06-10

  Compounds of the present disclosure are 2,2,2-tri-substituted acetamide derivatives of formula (I), its polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, useful as Glucokinase activator. Processes of their preparation are also described in the disclosure. The disclosure also describes method to characterize partial glucokinase activators.

  本公开涉及的化合物是式(I)的2,2,2-三取代乙酰胺衍生物，其多晶形态、立体异构体、前药、溶剂化物、药学上可接受的盐和制剂，可用作葡萄糖激酶激活剂。公开还描述了它们的制备过程。公开还描述了表征部分葡萄糖激酶激活剂的方法。
• 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
  申请人：Mookhtiar Kasim A.

  公开号：US08940900B2

  公开（公告）日：2015-01-27

  Compounds of the present disclosure are 2,2,2-tri-substituted acetamide derivatives of formula (I), its polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, useful as Glucokinase activator. Processes of their preparation are also described in the disclosure. The disclosure also describes method to characterize partial glucokinase activators.

  本公开涉及的化合物是式（I）的2,2,2-三取代乙酰胺衍生物，其多晶形态、立体异构体、前药、溶剂化物、药学上可接受的盐和制剂，可用作葡萄糖激酶激活剂。本公开还描述了它们的制备方法。本公开还描述了表征部分葡萄糖激酶激活剂的方法。
• SUBSTITUTED AMIDES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1496838B1

  公开（公告）日：2010-11-03
• US7348456B2
  申请人：——

  公开号：US7348456B2

  公开（公告）日：2008-03-25